Sigumir
Khavinson natural peptide complex derived from cartilage and bone tissue — studied for osteoarthritis, osteoporosis, and musculoskeletal degeneration support.
🔬 Mechanism of Action
Sigumir is a Khavinson Cytomax derived from cartilage and bone tissue, containing a dual-tissue peptide complex from chondrocytes and osteoblasts — uniquely targeting both halves of the musculoskeletal support system.
Sigumir modulates: (1) collagen type II and aggrecan genes in chondrocytes for cartilage matrix maintenance, (2) osteocalcin and osteopontin expression in osteoblasts for bone mineralization, (3) RANKL/OPG ratio — the master switch controlling osteoclast-mediated bone resorption, and (4) MMP expression balance (MMP-3, MMP-13 vs TIMPs) in cartilage.
Sigumir is the Cytomax counterpart to synthetic Cartalax (AED, cartilage-only) but provides broader coverage by also addressing bone metabolism. Used for osteoarthritis, osteoporosis, and post-fracture rehabilitation.
Source: PMID: 15677927
📜Background & History
Sigumir is the cartilage and bone Cytomax extract — natural counterpart to synthetic Cartalax.
🎯 Research Use Cases
- ✓Joint health
- ✓Osteoarthritis
- ✓Osteoporosis support
💉 Dosing Protocol
| Typical Dose | 1-2 capsules/day |
| Frequency | 1-2× daily for 10-30 day cycles |
| Half-Life | ~30 minutes (estimated) |
⚠️Safety & Considerations
Standard oral Cytomax capsule protocol. Can be combined with Cartalax (synthetic cartilage tripeptide) for enhanced joint support.
⚡Interactions & Contraindications
Standard Cytomax capsule protocol.
🔗Synergies & Common Stacks
Sigumir (Cytomax) + Cartalax (synthetic) = comprehensive musculoskeletal bioregulator protocol.